Vaxart's Revenue Soars on Government Contracts, Dynavax Deal Boosts Cash

TL;DR

**Vaxart's massive revenue jump and the Dynavax deal are a lifeline, but watch R&D spend and cash burn closely – this stock is still a high-risk bet on pipeline success.**

AI Summary

Vaxart, Inc. (VXRT) reported a significant increase in revenue from government contracts for the nine months ended September 30, 2025, reaching $131.44 million, a substantial rise from $12.85 million in the same period of 2024. Total revenue for the nine months ended September 30, 2025, was $133.02 million, up from $13.52 million in 2024. Despite this revenue growth, the company's net loss for the nine months ended September 30, 2025, was $38.72 million, an improvement from a net loss of $54.96 million in the prior year. Research and development expenses surged to $156.43 million for the nine months ended September 30, 2025, compared to $51.56 million in 2024, reflecting increased clinical trial activities. The company's cash and cash equivalents decreased to $16.88 million as of September 30, 2025, from $25.23 million at December 31, 2024. A key strategic development post-quarter was the exclusive license and collaboration agreement with Dynavax Technologies Corporation on November 4, 2025, for Vaxart's oral COVID-19 vaccine candidate, which included an upfront license fee of $25.0 million and a $5.0 million common stock purchase by Dynavax, providing a total of $30.0 million in new capital.

Why It Matters

Vaxart's substantial increase in government contract revenue and the recent Dynavax partnership are critical for investors, signaling potential validation of its oral vaccine platform and a much-needed cash infusion. This capital injection, totaling $30.0 million, directly addresses the company's previously stated liquidity concerns and going concern risk, potentially stabilizing its financial position for continued R&D. For employees and customers, this could mean sustained development of their oral COVID-19 vaccine candidate and other pipeline assets. In the competitive landscape, securing a partnership with Dynavax, a known vaccine adjuvant developer, could enhance Vaxart's credibility and accelerate its product development, potentially shifting market perception.

Risk Assessment

Risk Level: high — Vaxart explicitly states its cash, cash equivalents, and short-term investments of $28.8 million as of September 30, 2025, are not sufficient to fund planned operations for 12 months, indicating a significant going concern risk. While the subsequent $30.0 million from Dynavax helps, the company remains dependent on raising additional capital, and its net loss for the nine months ended September 30, 2025, was $38.72 million, demonstrating continued substantial cash burn.

Analyst Insight

Investors should closely monitor Vaxart's cash burn rate and the progress of its oral vaccine pipeline, particularly the COVID-19 candidate licensed to Dynavax. The recent $30.0 million capital injection provides a temporary buffer, but sustained long-term viability hinges on successful clinical development and further strategic partnerships or financing rounds. Consider this a speculative investment with high potential upside if clinical trials succeed, but also significant downside risk.

Financial Highlights

debt To Equity

6.81

revenue

$133.02M

operating Margin

N/A

total Assets

$208.99M

total Debt

$182.23M

net Income

-$38.72M

eps

N/A

gross Margin

N/A

cash Position

$16.88M

revenue Growth

+876.3%

Revenue Breakdown

Key Numbers

• $133.02M — Total Revenue (For the nine months ended September 30, 2025, up from $13.52 million in 2024)
• $131.44M — Revenue from government contracts (For the nine months ended September 30, 2025, a significant increase from $12.85 million in 2024)
• $38.72M — Net Loss (For the nine months ended September 30, 2025, an improvement from $54.96 million in 2024)
• $156.43M — Research and development expenses (For the nine months ended September 30, 2025, up from $51.56 million in 2024)
• $16.88M — Cash and cash equivalents (As of September 30, 2025, down from $25.23 million at December 31, 2024)
• $25.0M — Up-front license fee (Received from Dynavax Technologies Corporation on November 4, 2025)
• $5.0M — Common stock purchase (By Dynavax Technologies Corporation on November 4, 2025)
• $30.0M — Total capital received (From Dynavax Technologies Corporation transactions on November 4, 2025)
• $28.8M — Cash, cash equivalents and short-term investments (As of September 30, 2025, insufficient to fund operations for 12 months)
• 240,069,844 — Shares of common stock outstanding (As of November 6, 2025)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant and developer of oral recombinant protein vaccines
• Dynavax Technologies Corporation (company) — Partner in exclusive license and collaboration agreement for oral COVID-19 vaccine
• Citizens JMP Securities, LLC (company) — Manager for March 2025 At the Market Offering Agreement
• B. Riley Securities, Inc. (company) — Manager for March 2025 At the Market Offering Agreement
• Oppenheimer & Co. Inc. (company) — Underwriter for June 2024 registered direct offering
• RA Capital Healthcare Fund, L.P. (company) — Purchaser in January 2024 Securities Purchase Agreement
• Biomedical Advanced Research and Development Authority (regulator) — Source of government contract funding (HHS BARDA)
• U.S. Department of Health and Human Services (regulator) — Parent department of HHS BARDA
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Insufficient Cash for Operations [high — financial]: As of September 30, 2025, Vaxart reported $28.8 million in cash, cash equivalents, and short-term investments, which is insufficient to fund operations for the next 12 months. This raises concerns about the company's ability to meet its ongoing financial obligations without additional capital.
• High Research and Development Expenses [high — operational]: R&D expenses surged to $156.43 million for the nine months ended September 30, 2025, from $51.56 million in the prior year. This significant increase is attributed to expanded clinical trial activities, which, while necessary for product development, place a substantial financial burden on the company.
• Dependence on Government Contracts [medium — regulatory]: A substantial portion of Vaxart's revenue, $131.44 million for the nine months ended September 30, 2025, is derived from government contracts. Changes in government funding priorities, contract renewals, or regulatory shifts related to these contracts could materially impact the company's financial performance.
• Increasing Accounts Payable and Accrued Liabilities [medium — financial]: Total current liabilities increased significantly to $169.3 million as of September 30, 2025, from $90.88 million at December 31, 2024. This rise is largely due to increases in accounts payable ($53.08 million from $6.96 million) and other accrued current liabilities ($44.88 million from $11.38 million), indicating potential short-term cash flow pressures.
• Competition in Vaccine Market [medium — market]: The vaccine market is highly competitive, with established players and emerging companies developing novel technologies. Vaxart's success depends on its ability to differentiate its oral vaccine platform and gain market acceptance against existing and future competitors.
• Reliance on Key Partnerships [medium — operational]: The recent exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart's oral COVID-19 vaccine candidate highlights the company's reliance on strategic partnerships for development and commercialization. The success of these collaborations is critical for future revenue generation.

Industry Context

The biotechnology sector, particularly vaccine development, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on government funding, strategic partnerships, and capital markets to finance their operations. The competitive landscape is intense, with a constant drive for innovation in areas like oral delivery methods and novel vaccine platforms.

Regulatory Implications

Vaxart's reliance on government contracts exposes it to shifts in government funding priorities and procurement policies. Furthermore, the development and approval of any new vaccine candidate are subject to stringent regulatory review by agencies like the FDA, requiring extensive clinical trials and adherence to manufacturing standards.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate the success of the Dynavax collaboration.
3. Assess the sustainability of government contract revenue.
4. Analyze the impact of increased R&D spending on clinical trial progress.

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing significant revenue growth from government contracts but also increased R&D expenses and a decrease in cash reserves.
• 2025-11-04: Exclusive License and Collaboration Agreement with Dynavax Technologies Corporation — Provided $30.0 million in new capital through an upfront license fee ($25.0 million) and stock purchase ($5.0 million), bolstering the company's cash position for its oral COVID-19 vaccine candidate.
• 2025-12-31: End of Fiscal Year 2024 — Baseline for comparison of financial metrics, including cash and cash equivalents ($25.23 million).

Glossary

Unbilled receivable from government contracts

Revenue that has been earned but not yet billed to the government customer. This often occurs when work is in progress under a contract. (A significant component of Vaxart's current assets ($43.23 million as of Sep 30, 2025), reflecting substantial work performed under government contracts.)

Deferred government revenue

Payments received from the government for services or goods that have not yet been delivered or completed. It represents a liability until recognized as revenue. (A substantial current liability ($64.83 million as of Sep 30, 2025), indicating advance payments or unearned revenue related to government contracts.)

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents a reduction in stockholders' equity. (Vaxart has a significant accumulated deficit of ($515.24 million) as of Sep 30, 2025, common for development-stage biotechnology companies.)

Right-of-use assets, net

Assets recognized under lease accounting standards, representing the right to use an asset for a specified period. (Represents Vaxart's leased facilities and equipment, with a net value of $17.10 million as of Sep 30, 2025.)

Year-Over-Year Comparison

Vaxart has experienced a dramatic increase in revenue, primarily from government contracts, which grew from $12.85 million to $131.44 million for the nine-month period. This revenue surge has helped to offset rising R&D expenses, which more than tripled from $51.56 million to $156.43 million. Despite the improved revenue, the company's net loss narrowed but remains substantial. Cash reserves have declined, highlighting the ongoing need for capital, which was partially addressed by a recent collaboration agreement.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value VXRT * Indicate by chec
• $25.0 million — the Company an up-front license fee of $25.0 million and, pursuant to the Purchase Agreement
• $5.0 million — to the Purchase Agreement, to purchase $5.0 million of the Company's common stock at $ 0.45

Filing Documents

• vxrt20250930_10q.htm (10-Q) — 1921KB
• ex_887368.htm (EX-10.1) — 485KB
• ex_887369.htm (EX-10.2) — 141KB
• ex_856471.htm (EX-31.1) — 16KB
• ex_856472.htm (EX-31.2) — 16KB
• ex_856473.htm (EX-32.1) — 12KB
• 0001437749-25-034840.txt ( ) — 8791KB
• vxrt-20250930.xsd (EX-101.SCH) — 63KB
• vxrt-20250930_cal.xml (EX-101.CAL) — 47KB
• vxrt-20250930_def.xml (EX-101.DEF) — 440KB
• vxrt-20250930_lab.xml (EX-101.LAB) — 386KB
• vxrt-20250930_pre.xml (EX-101.PRE) — 472KB
• vxrt20250930_10q_htm.xml (XML) — 1345KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 5 Notes to the Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 Part II OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40

SIGNATURES

SIGNATURES 42 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") for the quarterly period ended September 30, 2025, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described herein under "Item 1A. Risk Factors." and those described in our Annual Report on Form 10-K for the year ended December 31, 2024, under "Item 1A. Risk Factors." You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statem

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements VAXART, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts ) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 16,880 $ 25,229 Short-term investments 11,913 26,494 Accounts receivable 42,716 5,761 Unbilled receivable from government contracts 43,229 6,208 Prepaid expenses and other current assets 2,632 4,568 Total current assets 117,370 68,260 Property and equipment, net 6,064 8,705 Prepaid clinical services, long-term 60,116 60,116 Right-of-use assets, net 17,097 20,404 Intangible assets, net 3,009 3,557 Goodwill 4,508 4,508 Other long-term assets 824 839 Total assets $ 208,988 $ 166,389 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 53,075 $ 6,963 Deferred government revenue 64,828 65,400 Other accrued current liabilities 44,882 11,378 Current portion of operating lease liability 3,783 3,077 Current portion of liability related to sale of future royalties 2,732 4,060 Total current liabilities 169,300 90,878 Operating lease liability, net of current portion 11,661 14,449 Liability related to sale of future royalties, net of current portion 782 1,698 Other long-term liabilities 489 439 Total liabilities 182,232 107,464 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock: $ 0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock: $ 0.0001 par value; 350,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 229,471,907 shares issued and 228,957,259 shares outstanding as of September 30, 2025 and 228,203,822 shares issued and 227,774,275 shares outstanding as of December 31, 2024 23 23 Additional paid-in capital 542,346 535,770 Treasury stock at cost, 514,648 shares as of Septembe

View Full Filing

View this 10-Q filing on SEC EDGAR